Product Description |
FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291. |
Product Background |
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging. |
Product Category |
Recombinant Protein |
Protein |
CD19 |
Synonyms |
CD19; B4; CVID3; Leu-12; MGC12802 |
Accession |
|
Species |
Human |
Biotinylated |
no |
Amino Acid Range |
Pro20-Lys291 |
Molecular Weight |
The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result. |
Activity |
Immobilized FITC-Compatible Human CD19, His Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for Anti-CD19 Antibody, hFc Tag with the EC50 of 9.3ng/ml determined by ELISA (QC Test). See testing image for detail. |
Product Tag |
C-His |
Expression System |
HEK293 |
Purity |
>95% as determined by Bis-Tris PAGE;>95% as determined by HPLC |
Endotoxin |
Less than 1 EU per ug by the LAL method. |
Form |
Lyophilized |
Shipping |
Shipped at ambient temperature. |
Formulation |
Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Stability And Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
|
FITC-Compatible Human CD19 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. |
|
|
FACS Analysis of Anti-CD19 CAR expression. 293T cells were transfected with anti-CD19-scFv and His tag. Cells were incubated with 10 ug/ml FITC-compatible Human CD19, His Tag and FITC-labeled protein control. Non-transfected 293T cells and FITC-labeled protein control were used as negative control. |
|
|
The purity of FITC-Compatible Human CD19 is greater than 95% as determined by SEC-HPLC. |
Product Resources
Related Products
Have more questions?
Check out our Frequently Asked Questions page for more details about product specifications, ordering, and shipments.
Contact Us
Recently viewed
